University of Chicago’s AbbVie ABBV Stock Holding History

University of Chicago’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,000	Closed	-$1.03M	–	6
2024 Q2	$1.03M	Buy	+6,000	New	+$994K	0.79%	4

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

University of Chicago's ABBV Position: Q3 2024 in Review

University of Chicago sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 6,000 shares — an estimated $1.03M sold.

University of Chicago first reported a position in ABBV in Q2 2024 and held it in 1 quarter. The position peaked at $1.03M in Q2 2024. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

University of Chicago reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
University of Chicago sold 6,000 AbbVie shares in Q3 2024, an estimated $1.03M.
University of Chicago first reported a position in AbbVie in Q2 2024 and held it in 1 quarter.
University of Chicago's AbbVie position peaked at $1.03M in Q2 2024.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on University of Chicago's 13F filing for Q3 2024, filed 16 Oct 2024.